Published in 2014 – Ann Oncol (2014) 25 (suppl 3): iii57-iii69.
Authors: P. Fenaux, D. Haase, G. F. Sanz, V. Santini, C. Buske
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis of ~70 years. The aetiology of MDS is known in only 15% of cases. The first clinical practice guidelines from ESMO cover the diagnosis and management of these rare syndromes and also include information on cytomorphology, cytogenetics, prognosis and risk assessment and supportive care.